HUMAN ISLET CELL TRANSPLANTATION FOR REVERSAL OF TYPE I DIABETES MELLITUS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。仅在美国就有大约80万人患有I型胰岛素依赖型糖尿病。尽管外源性胰岛素的发展和多种评估其递送模式的工具，但由于缺乏一致的葡萄糖稳态，I型糖尿病患者遭受多种并发症。1型糖尿病患者通常只有胰腺内分泌功能不足，因此只需要替换朗格汉斯胰岛。胰岛移植是一种生物替代策略，试图取代产生胰岛素的朗格汉斯胰岛，代表了一种潜在的治疗疾病的过程。本研究的目的是确定胰岛移植是否可以通过胰腺正常内分泌轴实现胰岛素独立或显著降低连续10例I型糖尿病患者的胰岛素需求。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Type I insulin-dependent diabetes mellitus affects approximately 800,000 people in the U.S. alone. Despite the development of exogenous insulin and multiple portocols evaluating its mode of delivery, type I diabetics suffer multiple complications due to the lack of consistent glucose homeostasis. Type I diabetics usually only have deficiency in the endocrine function of the pancreas, and therefore only require replacement of the Islets of Langerhans. Pancreatic islet transplantation is a biologic replacement strategy that attempts to replace the insulin producing Islets of Langerhans and represents a potential cure for the disease process. The goal of this study is to determine if pancreatic islet transplantation, via the normal endocrine axis of the pancreas, can achieve either insulin independence or a significant decrease in insulin requirements in 10 consecutive type I diabetic patients.